FY2025 EPS Estimates for ACAD Cut by Cantor Fitzgerald

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Research analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of ACADIA Pharmaceuticals in a research note issued to investors on Thursday, May 8th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will post earnings per share of $0.51 for the year, down from their prior estimate of $0.59. Cantor Fitzgerald has a “Overweight” rating and a $28.00 price objective on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share.

ACAD has been the subject of a number of other reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They issued a “hold” rating and a $22.00 price target for the company. StockNews.com upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 8th. UBS Group reduced their price target on shares of ACADIA Pharmaceuticals from $25.00 to $22.00 and set a “buy” rating for the company in a research note on Monday, April 28th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Tuesday, April 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.70.

ACADIA Pharmaceuticals Stock Up 3.0%

Shares of ACAD stock opened at $17.44 on Monday. The company has a 50 day moving average price of $15.83 and a 200-day moving average price of $16.98. ACADIA Pharmaceuticals has a 52 week low of $13.40 and a 52 week high of $20.68. The firm has a market capitalization of $2.92 billion, a PE ratio of 22.36 and a beta of 0.47.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.01. The business had revenue of $244.32 million during the quarter, compared to analyst estimates of $239.32 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. ACADIA Pharmaceuticals’s revenue was up 18.7% compared to the same quarter last year. During the same period last year, the business earned $0.10 EPS.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of ACADIA Pharmaceuticals by 9.0% in the first quarter. Vanguard Group Inc. now owns 15,203,234 shares of the biopharmaceutical company’s stock worth $252,526,000 after purchasing an additional 1,255,594 shares during the period. Assenagon Asset Management S.A. bought a new position in shares of ACADIA Pharmaceuticals in the first quarter worth approximately $60,845,000. First Trust Advisors LP boosted its position in shares of ACADIA Pharmaceuticals by 27.0% in the fourth quarter. First Trust Advisors LP now owns 2,700,125 shares of the biopharmaceutical company’s stock worth $49,547,000 after purchasing an additional 574,251 shares during the period. SG Americas Securities LLC boosted its position in shares of ACADIA Pharmaceuticals by 380.3% in the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock worth $45,576,000 after purchasing an additional 1,966,607 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in shares of ACADIA Pharmaceuticals in the fourth quarter worth approximately $40,935,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Insider Buying and Selling

In related news, Director Elizabeth A. Garofalo sold 4,919 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the transaction, the director now owns 17,595 shares of the company’s stock, valued at approximately $320,756.85. This trade represents a 21.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Mark C. Schneyer sold 3,171 shares of the firm’s stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $17.05, for a total transaction of $54,065.55. Following the completion of the transaction, the executive vice president now directly owns 56,889 shares in the company, valued at approximately $969,957.45. The trade was a 5.28% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,994 shares of company stock valued at $313,131. 26.50% of the stock is owned by insiders.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.